Every letter we have printed

Publishing the report number is a small accountability mechanism that already works. A number that can be quoted back to the issuing laboratory turns an image into something checkable, and the laboratories I have written to have all confirmed or denied within a week.

A sample that arrives at a laboratory in an unlabelled tube tells the analyst nothing about where it came from, and the report can only ever describe what was in the tube. The certificate says the material is pure; it cannot say the material is yours.

The cloned-template problem is easy to detect and nobody does the detecting. Identical column identifiers, identical retention times to two decimals and different product names across four documents is not a coincidence, and it takes one careful reading to see. Buyers do not read certificates; they file them.

The chain has a step nobody discusses: the person who selected the sample. If the seller chose which vial went to the laboratory, the result describes that vial and a selection decision, and the second half of that sentence never appears on the page.

The pharmacokinetic argument for and against intermittency is at least tractable from published data, even where clinical outcomes are not. A piece that worked through the exposure arithmetic without drawing clinical conclusions would fill a real gap.

Intermittent schedules are being used and are essentially unstudied, and the pharmacokinetics make the reasoning awkward: with a long half-life the concentration does not fall to nothing between doses, so an interrupted schedule is not the same as stopping and restarting.

As a prescriber I would push back on your framing of the maintenance gap. We are not practising without evidence; we are practising on pharmacological inference, which is what clinicians do in every field where the trial has not been run. Calling it unevidenced makes reasonable practice sound reckless.

I would like to see more attention to what people were doing before, not only after. A maintenance phase entered from a long stable period looks different from one entered after years of oscillation, and baseline history is almost never reported.

Values from cell-based assays depend on the expression system, the readout and the incubation, and figures from different laboratories are not comparable without those details. Comparison tables assembled from multiple papers are therefore assembling incommensurable numbers.

The structural work on this receptor is now good enough to explain several of the selectivity differences that used to be empirical observations. It is a genuine advance and it has not reached the popular accounts at all.

Your piece states that moving the injection day does not change total exposure, and I accept the arithmetic, but I want to record that it changed my experience considerably. I moved from Monday morning to Thursday evening and the two worst days now fall on a weekend. The drug is doing the same thing; my week is not.

Internalisation and recycling determine what a sustained exposure does over days, and almost all the published potency work is measured over minutes. The two timescales answer different questions and the shorter one is the one everybody quotes.

Emptying rate and symptom intensity correlate poorly at the individual level, which is one of the more interesting findings in the area. It means the mechanism is necessary and not sufficient, and coverage that treats them as the same thing is misleading.

What is missing from the mechanistic literature is anything about the microbiome, which is either an enormous omission or a sensible refusal to speculate. I have not been able to decide which, and neither, apparently, has anybody else.

Where a trial protocol specified a management approach, that fact belongs in any discussion of the trial’s tolerability results, because the results describe a managed population. It is usually in the methods and never in the summary.

System suitability is the section I would put first rather than fifth. If the tailing factor and the replicate precision are outside limits, the purity figure below them is arithmetic performed on an unfit separation. Everything else in the report is downstream of that box, and it is the box most often omitted.

Accreditation is worth less than buyers think and more than your article allows. A scope certificate tells you the laboratory has been audited for the methods listed on it, and nothing about whether your sample was run under one of them. Ask for the scope, then ask whether your test sits inside it.

Nobody has measured whether badges change behaviour. We assume they do because sellers pay for them, but sellers pay for a great many things whose effect has never been established. The absence of evidence on both sides of this argument is worth stating.

On our storefront we replaced the badge with a plain line of text giving the molecule, the date and the report number. Conversion fell for a fortnight and recovered, and the questions we now receive are better ones. I mention it because the commercial argument for badges is weaker than sellers assume.

I submitted a vial to one of these services last year, got a result three points below what the vendor advertised, and did not know what to do with it. Your article explains why: I had one measurement on one vial, no method comparison, and no way to know if my vial was representative. I still do not know what to do with it, but I understand the shape of not knowing.

Holding at an intermediate step is common practice and appears in no published protocol, which means the entire discussion of it rests on accounts rather than evidence. That should be stated whenever it is discussed.

A hold is a decision to accumulate more exposure at a given input, which is not the same as a decision to stop changing anything. The pharmacokinetics keep moving after the schedule stops.

In defence of the retention-time comparison your article is rude about: run against a properly characterised standard on a stated method, co-elution plus a matching mass is genuinely strong evidence. The weakness is not the logic, it is that the standard is usually a previous lot of the same product.

Any transposition of two residues preserves the intact mass exactly. So does a substitution that swaps one residue for another of the same composition. The set of molecules consistent with a given mass is not small, and describing a mass match as identity confirmation makes a claim about that whole set.

I have spent a week trying to reconcile a certificate’s stated mass of 4113.6 with a figure of 4111.1 I calculated from the sequence, and had convinced myself something was wrong with the vial. It was the isotope convention. Thank you, and also: how is this not stated on every certificate in existence?

Disposal is the part of this subject with actual legal content in most jurisdictions, and it is the part least discussed. The rules are public, they differ by locality, and they are not difficult to find.

Drawing through a stopper blunts a needle immediately, which is the argument for changing it before anything else happens. It is a practice recommendation with a physical basis rather than a ritual.

Storage of a reconstituted vial is where practice and evidence diverge most. The chemistry of the solution and the microbiology of a repeatedly entered container are two separate clocks, and only one of them is discussed. Material for research use is not approved for human use, and the storage question is the same regardless.

The archives are the good news. Where a service keeps every report it has issued and lets anybody search them, the badge becomes an index entry rather than a claim, and the whole problem changes shape. That capability exists and is barely used.

I run a laboratory that issues these reports and I read your criticism as fair. What we control is the document; what happens to our logo afterwards is outside our sight entirely. We would welcome a convention that let us take it back.

Credit where it is due: all four answered your questionnaire and answered it on the record. In my experience of trying to get straight answers out of laboratories in other sectors, that is not the normal outcome, and it says something about how these organisations see their role.

You note that no service offers sterility testing and that it takes fourteen days. Worth saying more plainly: a purity certificate and a sterility assurance are not merely different tests, they are different disciplines with different facilities, and no amount of chromatography will ever bear on it.

The lyophilisation step is sometimes described as though it sterilised the material. It does not; it removes water, and organisms and their fragments survive it routinely.

The recombinant reagent alternatives have matured and are accepted in several pharmacopoeias now. That development removes the last practical objection anybody raised about supply of the traditional reagent.

I photograph every cake now because of an earlier piece of yours, and last month it paid for itself. Two vials from the same box, one a proper matte plug and one a collapsed glassy disc. The supplier replaced both without argument when I sent the photographs.

A quibble about depyrogenation. You imply an operation describing autoclaving alone has skipped a step, but depyrogenation of glass is only necessary if the incoming glass carries endotoxin. Vials supplied ready-to-use from a component manufacturer arrive already depyrogenated and certified as such.

Your table of responses records four declines citing research-use-only status, and you call that a legally sound answer. It is also the answer that ends the conversation. What would you have a supplier say instead?

The phrase dose-limiting has a precise meaning in trial design and a loose one everywhere else. In a protocol it names the point at which escalation stops; in general use it names discomfort. The two are frequently conflated in coverage of the same study.

Discontinuation rates for adverse effects in the published trials are the most useful single figure in this whole subject, because they capture the point at which symptoms actually changed a decision. They are also considerably lower than the incidence figures that get quoted.

Serum concentration and body stores are different quantities for most micronutrients, and the relationship is regulated. A normal serum value is consistent with a range of underlying states, which is why the good assays are the indirect ones.